Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study-Reference-Cited by-同舟云学术

Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study

Published:2017-11 Issue:5 Volume:198 Page:1054-1060
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Tombal Bertrand¹,Cornel Erik B.²,Persad Raj³,Stari Anny⁴,Gómez Veiga Francisco⁵,Schulman Claude⁶

Affiliation:

1. Cliniques Universitaires Saint-Luc, Brussels, Belgium

2. Department of Urology, Ziekenhuisgroep Twente, Hengelo, the Netherlands

3. Department of Urology, University Hospitals Bristol National Health Service Foundation Trust, Bristol, United Kingdom

4. Astellas Pharma Medical Affairs EMEA, Chertsey, United Kingdom

5. Salamanca University Hospital and Translational Research Group of Urology GITUR-IBSAL, Salamanca, Spain

6. Clinic E Cavell and University of Brussels, Brussels, Belgium

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference14 articles.

1. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer;Mottet;Eur Urol,2011

2. Mottet N, Bellmunt J, Briers E et al: European Association of Urology Guidelines on Prostate Cancer. Updated March 2016. Available at http://uroweb.org/guideline/prostate-cancer/. Accessed February 28, 2017.

3. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?;Pickles;BJU Int,2012

4. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT;Klotz;J Clin Oncol,2015

5. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer;Crawford;J Urol,2006

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies;BJUI Compass;2024-01-10

2. Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review;Cancers;2023-07-03

3. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer;Expert Review of Anticancer Therapy;2022-06-03

4. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer;Journal of Urology;2021-11

5. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial;Radiotherapy and Oncology;2021-07